Table 1.
Patient and transplant characteristics
| No. (%) | |
|---|---|
| Age at transplantation, y | |
| ≤6 | 638 (57) |
| 7-15 | 439 (40) |
| 16-25 | 33 (3) |
| Sex | |
| Male/female | 696 (63)/414 (37) |
| Red blood cell transfusions prior to transplantation | |
| <20 | 40 (4) |
| 20-50 | 304 (27) |
| >50 | 634 (57) |
| Not reported | 132 (12) |
| Iron chelation | |
| Adequate | 117 (11) |
| Inadequate | 981 (88) |
| Not reported | 12 (1) |
| Hepatomegaly | |
| Absent | 280 (25) |
| Present | 806 (73) |
| Not reported | 24 (2) |
| Donor type | |
| HLA-matched relative | 677 (61) |
| HLA-mismatched relative | 78 (7) |
| HLA-matched unrelated | 252 (23) |
| HLA-mismatched unrelated | 103 (9) |
| Graft type | |
| Bone marrow | 321 (29) |
| Peripheral blood | 682 (61) |
| Cord blood | 107 (10) |
| In vivo T-cell depletion | |
| Yes/none | 827 (75)/283 (25) |
| Conditioning regimen | |
| BU/Cy/TT/FLU | 376 (34) |
| BU/Cy/FLU | 259 (23) |
| BU/Cy | 249 (22) |
| Treosulfan/TT/FLU | 169 (15) |
| BU or melphalan ± TT ± FLU | 57 (5) |
| GVHD prophylaxis | |
| Calcineurin inhibitor/methotrexate/mycophenolate | 187 (17) |
| Calcineurin inhibitor/methotrexate | 446 (40) |
| Calcineurin inhibitor/mycophenolate | 350 (32) |
| Calcineurin inhibitor alone | 31 (3) |
| Posttransplant Cy/cyclosporine/mycophenolate | 96 (9) |